1198090-73-1 Usage
Description
N-2-Hydroxy-3-[[2-(Methoxyphenoxy)ethyl]amine Carvedilol, also known as Carvedilol EP Impurity A, is a chemical compound that arises as an impurity during the manufacturing process of Carvedilol (C184625). This impurity is characterized by its unique molecular structure, which includes a hydroxyl group and a methoxyphenoxyethylamine moiety.
Uses
Used in Pharmaceutical Industry:
N-2-Hydroxy-3-[[2-(Methoxyphenoxy)ethyl]amine Carvedilol is used as a process impurity in the production of Carvedilol, a medication primarily used for the treatment of hypertension, heart failure, and myocardial infarction. The presence of this impurity is monitored and controlled to ensure the safety, efficacy, and quality of the final Carvedilol product.
In the pharmaceutical industry, the management and control of impurities like Carvedilol EP Impurity A are crucial for maintaining the overall quality and safety of the drugs being produced. This impurity may be further studied to understand its potential effects on the drug's pharmacological properties and to develop methods for its removal or reduction during the manufacturing process.
Check Digit Verification of cas no
The CAS Registry Mumber 1198090-73-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,8,0,9 and 0 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1198090-73:
(9*1)+(8*1)+(7*9)+(6*8)+(5*0)+(4*9)+(3*0)+(2*7)+(1*3)=181
181 % 10 = 1
So 1198090-73-1 is a valid CAS Registry Number.
1198090-73-1Relevant articles and documents
Synthesis and characterization of potential impurities of carvedilol, an antihypertensive drug
Rao, Somisetti Narender,Sitaramaiah, Devarasetty,Srimannarayana, Kema,Rao, Challa Nageswar,Rao, Peddi Srinivasa,Babu, K. Sudhakar
, p. 85 - 93 (2011/03/19)
Carvedilol (Coreg) is a nonselective -adrenergic blocking agent with vasodilating activity. It is used for the treatment of congestive heart failure and hypertension. During the bulk synthesis of carvedilol, we have observed six impurities: Imp-I, Imp-II, Imp-III, Imp-IV, Imp-V, and Imp-VI. The present work describes the synthesis and characterization of these impurities. Copyright